Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
14.11
-0.53 (-3.62%)
At close: Aug 31, 2026, 4:00 PM EDT
14.01
-0.10 (-0.71%)
After-hours: Aug 31, 2026, 7:39 PM EDT
Alpha Tau Medical Employees
Alpha Tau Medical had 121 employees as of December 31, 2025. The number of employees decreased by 4 or -3.20% compared to the previous year.
Employees
121
Change (1Y)
-4
Growth (1Y)
-3.20%
Revenue / Employee
n/a
Profits / Employee
-$765,074
Market Cap
1.30B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 121 | -4 | -3.20% |
| Dec 31, 2024 | 125 | 4 | 3.31% |
| Dec 31, 2023 | 121 | 27 | 28.72% |
| Dec 31, 2022 | 94 | 11 | 13.25% |
| Dec 31, 2021 | 83 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 678 |
| MeiraGTx Holdings | 393 |
| Omeros | 175 |
| MoonLake Immunotherapeutics | 130 |
| ORIC Pharmaceuticals | 111 |
| Cullinan Therapeutics | 109 |
| Vor Biopharma | 76 |
| Savara | 70 |
DRTS News
- 11 hours ago - Alpha Tau completes patient enrollment in IMPACT study - TheFly
- 12 hours ago - Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions - GlobeNewsWire
- 20 days ago - Alpha Tau price target raised to $16 from $15 at H.C. Wainwright - TheFly
- 21 days ago - Alpha Tau reports Q2 EPS (25c), consensus (14c) - TheFly
- 21 days ago - Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) - GlobeNewsWire
- 5 weeks ago - Alpha Tau reports Alpha DaRT combination study results - TheFly
- 5 weeks ago - Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success - GlobeNewsWire
- 6 weeks ago - Alpha Tau treats first patient in ADMIRE study for recurrent skin cancer - TheFly